RxDoctor Payments Data

Edmund Lew, MD

Family Medicine · Glendale, CANPI 1528027836

Payments from drug & device makers

$2,240in general payments, 2019–2025

Across 89 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$383
  • Abbott$274
  • Amgen$244
  • Exact Sciences$169
  • Cleerly, Inc.$163
  • Lilly USA, LLC$145
  • plus $863 from 12 others

What the payments were for

  • Food & beverage$2,240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,240 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$448,336
Medicare patients
493
Services billed
4,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$110,152
EliquisApixaban221$110,122
JardianceEmpagliflozin83$84,987
MounjaroTirzepatide40$80,964
JanuviaSitagliptin Phosphate86$56,527
TrulicityDulaglutide30$45,105
FarxigaDapagliflozin Propanediol37$41,338
RybelsusSemaglutide14$29,678
EntrestoSacubitril/Valsartan18$10,863
Np ThyroidThyroid,pork119$9,164
Cinacalcet Hcl31$7,784
MyrbetriqMirabegron12$6,982
NamzaricMemantine Hcl/Donepezil Hcl23$6,754
ProgesteroneProgesterone, Micronized74$5,711
Rosuvastatin Calcium337$5,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$383$139,83083 claims
Lilly USA, LLCMounjaro, Trulicity$145$126,06870 claims
PfizerEliquis, Paxlovid$77$111,551250 claims
MerckJanuvia$118$56,52786 claims
AstraZenecaFarxiga$81$41,33837 claims
AbbVieNamzaric, Armour Thyroid$115$9,97173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →